Current Edition

Johnson & Johnson

Pressed by Wall Street, pharma executives signal openness to M&A

Pharmaceutical executives are getting asked the same question. With many large drugmakers flush with cash, and valuations of publicly traded biotech companies crashing, analysts on …

Continue Reading →
coronavirus vaccine

J&J foresees end to not-for-profit sales of coronavirus vaccine

J&J has recorded far fewer sales of its coronavirus vaccine than competitors Pfizer and Moderna, partly due to its not-for-profit pricing but also to a …

Continue Reading →

Pfizer, marking fast research pace, starts key trial of RSV vaccine

A vaccine against RSV has proven elusive despite decades of attempts. Pfizer is moving at a surprisingly quick pace to catch up to rivals led …

Continue Reading →

FDA grants full approval to Pfizer, BioNTech’s coronavirus vaccine

The Food and Drug Administration on Monday granted full approval to Pfizer and BioNTech’s coronavirus vaccine, a long-awaited decision that government officials hope could help …

Continue Reading →